Trial · NCT03856866
Hydroxychloroquine Administration for Reduction of Pexophagy
NCT03856866, Phase 2, Completed, The Hospital for Sick Children
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hydroxychloroquine Administration for Reduction of Pexophagy. Trials, record NCT03856866. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03856866
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hydroxychloroquine Administration for Reduction of Pexophagy
- NCT number
- NCT03856866
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- The Hospital for Sick Children
- Conditions
- Zellweger Syndrome, Peroxisome Biogenesis Disorders
- Interventions
- Hydroxychloroquine, Placebo
- First posted
- 2019-02-27
- Last updated
- 2020-12-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Electroretinogram (ERG) voltage changes. | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Electroretinograms are a diagnostic test that measures the electric activity within cells in response to stimulus. ERG voltages are depressed in peroxisomal disease, and the quantitative evaluation of ERG voltage is another measure that has been used as an endpoint for clinical trials in peroxisomal disease. Change in b-wave voltage before and after treatment period. |
| Primary | Change in the red blood cell levels of plasmalogen. | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Change in the red blood cell levels of plasmalogen (18:0 dimethylacetals/18:0 ratio). |
| Primary | Change in the plasma levels of phytanic acid. | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Change in the plasma levels of phytanic acid. |
| Primary | Change in the plasma levels of very-long chain fatty acids. | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Change in the plasma levels of very-long chain fatty acids (C26/C22). |
| Secondary | Eye examination: Optical Coherence Tomography | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Optical coherence tomography is an imaging study of the retina. OCT is routinely performed in clinical management of patients with peroxisomal disease. |
| Secondary | Eye examination: Visual Acuity | 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm. | Visual acuity testing evaluates the visual performance of patients using the reading of a logMAR chart. Visual acuity testing is routinely performed in clinical management of patients with peroxisomal disease. |
| Secondary | Pediatric Inventory for Parents (PIP) following the treatment arms. | 36 week. Measurements following each treatment arm. | The PIP is a validated measure of parental stress related to the care for children with chronic illness. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03856866
GET https://conductscience.org/api/trials/v1/NCT03856866/registered